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COMMENTARY
Using PET imaging to track STING-induced
interferon signaling
Enitome E. Bafora,1 and Howard A. Younga,1
In the 19th century, Ilya Metchnikoff defined and
broadened our initial understanding of phagocytosis
and, in 1908, went on to show that a cellular compo-
nent (i.e., DNA) stimulates immune responses (1).
About a century later, Janeway conceptualized pattern
recognition receptors (PRRs) and pathogen-associated
molecular patterns (PAMPs) (2). Since then, we know
that PAMP recognition by innate immune cells via
PRRs activates the production of several cytokines, in-
cluding interferons (IFNs), with the eventual recruitment
of lymphocytes. Subsequent research discovered that
innate immune recognition of double-stranded DNA
(dsDNA) triggers autoimmune diseases (3). However,
before the discovery of dsDNA sensors, an endoplasmic
reticulum (ER) protein encoded by the TMEM173 gene,
known as a stimulator of IFN genes (STING), was identi-
fied as a significant factor involving DNA recognition in
innate immunity (4). Subsequently, scientists discovered
that the direct cytosolic DNA sensor (cGAS) activates
the expression of type 1 IFNs (5). Today, it is well
known that activation of cGAS-cGAMP-STING signal-
ing is triggered by cytosolic DNA and is necessary for
antimicrobial and antitumor immune responses. In
PNAS, Liang et al. (6) describe an innovative process
for monitoring STING-induced IFN signaling. Induction
of IFN signaling by STING occurs on detection of cyto-
plasmic DNA, which may be tumor- or microbial-derived.
STING is activated when cGAS catalyzes the synthesis
of cyclic dinucleotides (CDNs) including 2′3′-cGAMP
(7). STING is translocated from the ER to the perinucleus,
Fig. 1. Proposed noninvasive tracking of STING-induced IFN signaling using [18F]FLT PET by Liang et al. (6) (created
using Biorender).
aLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702
Author contributions: E.E.B. and H.A.Y. wrote the paper.
The authors declare no competing interest.
Published under the PNAS license.
1To whom correspondence may be addressed. Email: Enitome.Bafor@nih.gov or younghow@mail.nih.gov.
See companion article, “STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET
imaging,” 10.1073/pnas.2105390118.
Published September 14, 2021.











phosphorylated by TANK-binding kinase 1 (TBK1) and recruits IFN
regulatory factor 3 (IRF3), which in turn is phosphorylated by TBK1,
forms a dimer, and enters the nucleus. Phosphorylated IRF3 activates
transcription of type 1 IFNs and other relevant cytokines (8) which
bind to the heterodimeric IFN receptors (IFNAR1 and IFNAR2)
and recruits Janus family kinase 1(Jak1) and tyrosine kinase 2
(Tyk2), which in turn phosphorylates and activates IFNAR1 and
IFNAR2. Activated IFNAR1 and 2 phosphorylate signal trans-
ducers and activators of transcription (STAT) proteins (STAT1
and STAT2), which are transferred to the nucleus along with IFN
regulatory factor 9 (IRF9), to enhance transcription of IFN target
genes (9) and subsequently activate the innate and adaptive
immune responses.
The discovery of the STING signaling pathway led to further
investigation into the antitumor effects of STING. As a majority of
cancer patients fail to respond to immune checkpoint inhibitors,
the STING–IFN signaling pathway has become an alternative im-
munotherapy target. Expression of type1 IFN and related genes in
tumors correlates positively with infiltration of T cells into the tu-
mor microenvironment and support an antitumor role for type 1
IFNs (10). STING agonists are therefore currently being investi-
gated for cancer immunotherapies. However, since most STING
agonists are based on CDNs, they are delivered intratumorally
due to the poor metabolic stability of these agents. In addition,
there are recent concerns about the potential inhibitory impact of
STING on antitumor responses, with inhibition of T cell prolifera-
tion and promotion of T cell death reported (11). Thus, STING can
also potentially impair the adaptive immune response. Taken to-
gether, the effective in vivo monitoring and tracking of STING–
IFN signaling on treatment with STING agonists is vital.
In PNAS, Liang et al. describe an innovative
process for monitoring STING-induced
IFN signaling.
Liang et al. (6) used a non-CDN STING agonist (diABZI-
compound 3 triydrochloride of the amidobenzimidazoles family)
to promote STING up-regulation and proceeded to noninvasively
track downstream metabolic IFN signaling in a pancreatic ductal
adenocarcinoma (PDAC) model via positron emission tomogra-
phy (PET). PET is utilized in imaging the systemic distribution of
radiolabeled compounds such as fluoropyrimidines (12) and,
therefore, is an innovative addition for PDAC and tumor imaging
in general. The authors show, among other dysregulated metab-
olites, that type 1 IFNs triggered the up-regulation of genes
associated with nucleoside breakdown, specifically thymidine
phosphorylase (TYMP). TYMP catalyzes the reversible phospho-
rolysis of thymidine and deoxyuridine and is essential for the
stability of mitochondrial DNA (13). TYMP is identical to platelet-
derived endothelial growth factor, a tumor angiogenic factor (14)
that is increased in several tumors and associated with increased
tumor invasiveness and decreased survival (15). Type 1 IFNs in-
duce TYMP in patients with advanced malignancies, a finding that
was also observed by Liang et al. (6) with type 1 IFN-TYMP elevation
in PDAC. This effect was relevant as uptake of nucleoside analog
PET probes is dependent on nucleoside levels (16) and it provided
further support for the study’s application. The consistency of
TYMP expression in tumors also makes it a reliable biomarker
for IFN signaling.
Since TYMP expression promotes tumor 3′-deoxy-3′fluorothy-
midine (FLT) PET probe accumulation in vivo (17), the authors
considered that IFN-induced TYMP could be leveraged for
detecting STING-induced IFN signaling, and these processes
can be monitored via PET imaging. In PET imaging, where long-
term pharmacodynamic parameters are required, compounds re-
sistant to TYMP and with long half-lives should be utilized. As
such, TYMP-resistant fluoropyrimidines labeled with [18F] are cur-
rently in use for imaging purposes. For instance, FLT, as shown in
Liang et al. (6), is a specific substrate of thymidine kinase 1 (TK1)
and has been successfully used in tumor studies (18). Its tissue
uptake is correlated with cellular proliferation (18), thus making
it a valuable tool for a tumor proliferation rate measurement. The
authors showed that type 1 IFNs promote [18F]FLT PET probe
accumulation in PDAC cells in vitro through the transcriptional
up-regulation of TYMP and depletion of the sterile alpha motif
and HD domain-containing protein 1 (SAMHD1)–produced thymi-
dine (dT), an endogenous inhibitor of [18F]FLT uptake. However,
the use of FLT is limited in its application to detect metastasis in
tissues with a high proliferation rate, such as the bone marrow (19).
Other analogs such as [1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-
thymine, FMAU] can be utilized to overcome this limitation with
FLT. It would have been an added strength if the authors had com-
pared FLT and FMAU, considering the broader implications of the
proposed procedure. Nonetheless, it does not detract from the
usefulness of the procedure.
Induction of cellular perturbations and cytosolic DNA accumu-
lation can trigger STING induction and IFN expression (20). The
authors utilized this phenomenon when they showed that STING-
induced IFN signaling triggered in vitro and in vivo TYMP expres-
sion as well as up-regulation of IFNB1 transcripts, suggesting a
comparable transcriptional alteration in PDAC cell-autonomous
IFN signaling downstream of STING activation. The authors also
demonstrated a role for STING in regulating PDAC IFN signaling
in vivo using SUIT2 cells engineered to express an active STING
mutant (SUIT2-TetR-STINGR284M) under doxycycline-inducible
promoter control. Their results showed impairment of PDAC cell
proliferation and TYMP expression, which was overcome by
inhibiting JAK1/2. Furthermore, the authors showed that STING
could induce metabolic alterations that can be visualized by [18F]
FLT PET, a relevant addition to the procedure’s usefulness.
Immunometabolism is associated with the polarization of im-
mune cells, and metabolites such as succinates or glucocorti-
coids link directly to different inflammatory statuses. Therefore,
tracking metabolites specific for STING-induced IFN immuno-
metabolism will prove relevant as pharmacodynamic markers
of in vivo IFN responses induced by STING agonists. To merge
their findings, the authors utilized the concept of STING agonist-
driven TYMP expression to promote the accumulation of [18F]
FLT in vitro and in vivo. They used the diABZI-compound 3 to
trigger a dose-dependent increase of IFNB1 transcripts and
TYMP in SUIT2 PDAC cells. As shown in this article (6), STING-
associated immunometabolism within tumors can be effectively
tracked using radiolabeled compounds that accumulate within
tumors. While the use of PET is not new in tumor studies, utilizing
PET for STING agonist-induced IFN signaling in tumors can pro-
vide useful insight for tumor immunotherapy. Worthy of mention
are reports of other novel non-CDN systemic STING agonists
(SR-717 and MSA-2) which show favorable pharmacokinetic im-
provements over earlier CDN-based STING agonists (13, 21).
These novel systemic non-CDN STING agonists provide an al-
ternative approach for targeting the STING–IFN pathway. As
such, it would therefore be worthwhile to utilize the [18F]FLT
PET imaging to evaluate their pharmacodynamic profiles for an
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effective comparison. A schematic of the proposed utilization of
PET imaging in IFN signaling is shown in Fig. 1.
The authors, therefore, provide an interesting noninvasive
procedure for monitoring STING agonist induced IFN signaling,
which can prove relevant in tracking local and systemic IFN
activities and enhance tumor immunotherapy.
Acknowledgments
This work was supported by the Intramural Research Program of the Center for
Cancer Research, National Cancer Institute. The views expressed in this article
are those of the authors and do not necessarily reflect the official policy or
position of the Department of Health and Human Services, nor does mention of
trade names, commercial products, or organizations imply endorsement by the
United States Government.
1 T. P. Stossel, “The early history of phagocytosis” in Advances in Cell and Molecular Biology of Membranes and Organelles, S. Gordon, Ed. (JAI Press, 1999), pp.
3–18.
2 R. Medzhitov, C. Janeway, Jr, Innate immunity. N. Engl. J. Med. 343, 338–344 (2000).
3 A. Ablasser, C. Hertrich, R. Waßermann, V. Hornung, Nucleic acid driven sterile inflammation. Clin. Immunol. 147, 207–215 (2013).
4 H. Ishikawa, G. N. Barber, STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).
5 J. Wu et al., Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
6 K. Liang et al., STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging. Proc. Natl. Acad. Sci.
U.S.A. 118, e2105390118 (2021).
7 L. Sun, J. Wu, F. Du, X. Chen, Z. J. Chen, Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791
(2013).
8 J. Tao, X. Zhou, Z. Jiang, cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life 68, 858–870 (2016).
9 J. Piehler, C. Thomas, K. C. Garcia, G. Schreiber, Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.
Immunol. Rev. 250, 317–334 (2012).
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